Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Thorac Surg Clin. 2004 Nov;14(4):531-42.

Multimodality therapy in mesothelioma: role of chemotherapy.

Author information

  • Nevada Cancer Institute, 10,000 West Charleston Boulevard, Suite 260, Las Vegas, NV 89135, USA. nvogelza@nvcancer.org

Abstract

The few long-term survivors of MPM have been cured with radical surgical extirpation often followed by radiation therapy and adjuvant chemotherapy. The combination of pemetrexed and cisplatin recently was shown to improve survival over treatment with cisplatin alone. Given the size and robustness of that trial, the combination should be the new standard treatment for this cancer. Combined modality approaches to therapy, including surgery, radiation, and chemotherapy, are becoming the standard of care in patients with resectable mesothelioma. Two phase II studies have demonstrated that neoadjuvant chemotherapy is safe and apparently effective. A third phase II trial will use the combination of pemetrexed plus cisplatin preoperatively followed by surgery and radiation for patients with T1-3 N0-2 mesothelioma. If the statistical analysis of this study shows a measurable pathologic complete response rate and a median survival that exceeds the current expected value of 20 to 24 months, a phase III trial comparing surgery and radiation to surgery, radiation, and chemotherapy will be considered.

PMID:
15559060
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk